180 related articles for article (PubMed ID: 28882992)
21. Hepatic and pulmonary microsomal metabolism of naphthalene to glutathione adducts: factors affecting the relative rates of conjugate formation.
Buckpitt AR; Bahnson LS; Franklin RB
J Pharmacol Exp Ther; 1984 Nov; 231(2):291-300. PubMed ID: 6491983
[TBL] [Abstract][Full Text] [Related]
22. Bioactivation of phencyclidine in rat and human liver microsomes and recombinant P450 2B enzymes: evidence for the formation of a novel quinone methide intermediate.
Driscoll JP; Kornecki K; Wolkowski JP; Chupak L; Kalgutkar AS; O'Donnell JP
Chem Res Toxicol; 2007 Oct; 20(10):1488-97. PubMed ID: 17892269
[TBL] [Abstract][Full Text] [Related]
23. Ponatinib for the treatment of adult patients with resistant or intolerant Chronic-Phase Chronic Myeloid Leukemia.
Haddad FG; Issa GC; Jabbour E; Yilmaz M
Expert Opin Pharmacother; 2022 May; 23(7):751-758. PubMed ID: 35412404
[TBL] [Abstract][Full Text] [Related]
24. A multi-parameter in vitro screen in human stem cell-derived cardiomyocytes identifies ponatinib-induced structural and functional cardiac toxicity.
Talbert DR; Doherty KR; Trusk PB; Moran DM; Shell SA; Bacus S
Toxicol Sci; 2015 Jan; 143(1):147-55. PubMed ID: 25304212
[TBL] [Abstract][Full Text] [Related]
25. The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib.
Parker WT; Yeung DT; Yeoman AL; Altamura HK; Jamison BA; Field CR; Hodgson JG; Lustgarten S; Rivera VM; Hughes TP; Branford S
Blood; 2016 Apr; 127(15):1870-80. PubMed ID: 26773037
[TBL] [Abstract][Full Text] [Related]
26. Clinical outcomes in patients with Philadelphia chromosome-positive leukemia treated with ponatinib in routine clinical practice-data from a Belgian registry.
Devos T; Havelange V; Theunissen K; Meers S; Benghiat FS; Gadisseur A; Vanstraelen G; Vellemans H; Bailly B; Granacher N; Lewalle P; De Becker A; Van Eygen K; Janssen M; Triffet A; Vrelust I; Deeren D; Mazure D; Bekaert J; Beck M; Selleslag D
Ann Hematol; 2021 Jul; 100(7):1723-1732. PubMed ID: 33942128
[TBL] [Abstract][Full Text] [Related]
27. Ponatinib: A Third-Generation Inhibitor for the Treatment of CML.
Wehrle J; von Bubnoff N
Recent Results Cancer Res; 2018; 212():109-118. PubMed ID: 30069627
[TBL] [Abstract][Full Text] [Related]
28. 3-aminobenzanthrone, a human metabolite of the environmental pollutant 3-nitrobenzanthrone, forms DNA adducts after metabolic activation by human and rat liver microsomes: evidence for activation by cytochrome P450 1A1 and P450 1A2.
Arlt VM; Hewer A; Sorg BL; Schmeiser HH; Phillips DH; Stiborova M
Chem Res Toxicol; 2004 Aug; 17(8):1092-101. PubMed ID: 15310241
[TBL] [Abstract][Full Text] [Related]
29. Role of human glutathione S-transferases in the inactivation of reactive metabolites of clozapine.
Dragovic S; Boerma JS; van Bergen L; Vermeulen NP; Commandeur JN
Chem Res Toxicol; 2010 Sep; 23(9):1467-76. PubMed ID: 20849150
[TBL] [Abstract][Full Text] [Related]
30. Management of ponatinib dosing in chronic myeloid leukemia patients.
Sacha T; Szczepanek E
J Physiol Pharmacol; 2021 Jun; 72(3):. PubMed ID: 34810285
[TBL] [Abstract][Full Text] [Related]
31. Identification of a novel glutathione conjugate of flutamide in incubations with human liver microsomes.
Kang P; Dalvie D; Smith E; Zhou S; Deese A
Drug Metab Dispos; 2007 Jul; 35(7):1081-8. PubMed ID: 17403914
[TBL] [Abstract][Full Text] [Related]
32. Expression of human glutathione S-transferase P1 confers resistance to benzo[a]pyrene or benzo[a]pyrene-7,8-dihydrodiol mutagenesis, macromolecular alkylation and formation of stable N2-Gua-BPDE adducts in stably transfected V79MZ cells co-expressing hCYP1A1.
Kushman ME; Kabler SL; Fleming MH; Ravoori S; Gupta RC; Doehmer J; Morrow CS; Townsend AJ
Carcinogenesis; 2007 Jan; 28(1):207-14. PubMed ID: 16885195
[TBL] [Abstract][Full Text] [Related]
33. One-electron oxidation of diclofenac by human cytochrome P450s as a potential bioactivation mechanism for formation of 2'-(glutathion-S-yl)-deschloro-diclofenac.
Boerma JS; Vermeulen NP; Commandeur JN
Chem Biol Interact; 2014 Jan; 207():32-40. PubMed ID: 24246759
[TBL] [Abstract][Full Text] [Related]
34. Metabolic activation of racemic and enantiomeric trans-8, 9-dihydroxy-8,9-dihydrodibenzo[a,l]pyrene (dibenzo[def,p]chrysene) to dibenzo[a,l]pyrene-bis-dihydrodiols by induced rat liver microsomes and a recombinant human P450 1A1 system: the role of the K-region-derived metabolic intermediates in the formation of dibenzo[a,l]pyrene-DNA adducts.
Nesnow S; Davis C; Padgett W; George M; Lambert G; Meyers F; Allison J; Adams L; King LC
Chem Res Toxicol; 1998 Dec; 11(12):1596-607. PubMed ID: 9860506
[TBL] [Abstract][Full Text] [Related]
35. The Outcomes of Ponatinib Therapy in Patients With Chronic Myeloid Leukemia Resistant or Intolerant to Previous Tyrosine Kinase Inhibitors, Treated in Poland Within the Donation Program.
Sacha T; Szczepanek E; Dumnicka P; Góra-Tybor J; Niesiobędzka-Krężel J; Prejzner W; Wasilewska E; Kłoczko J; Ciepłuch H; Makowska W; Patkowska E; Wasilewska J; Bober G; Kopera M; Wichary R; Kroll-Balcerzak R; Gromek T; Wach M; Rudkowska-Kazanowska A; Świniarska M; Paczkowska E; Biernat M; Joks M; Oller M; Kasza R; Kostyra A; Gil J; Grzybowska-Izydorczyk O
Clin Lymphoma Myeloma Leuk; 2022 Jun; 22(6):405-415. PubMed ID: 34933827
[TBL] [Abstract][Full Text] [Related]
36. Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial.
Lipton JH; Chuah C; Guerci-Bresler A; Rosti G; Simpson D; Assouline S; Etienne G; Nicolini FE; le Coutre P; Clark RE; Stenke L; Andorsky D; Oehler V; Lustgarten S; Rivera VM; Clackson T; Haluska FG; Baccarani M; Cortes JE; Guilhot F; Hochhaus A; Hughes T; Kantarjian HM; Shah NP; Talpaz M; Deininger MW;
Lancet Oncol; 2016 May; 17(5):612-21. PubMed ID: 27083332
[TBL] [Abstract][Full Text] [Related]
37. Combination of panobinostat with ponatinib synergistically overcomes imatinib-resistant CML cells.
Matsuda Y; Yamauchi T; Hosono N; Uzui K; Negoro E; Morinaga K; Nishi R; Yoshida A; Kimura S; Maekawa T; Ueda T
Cancer Sci; 2016 Jul; 107(7):1029-38. PubMed ID: 27166836
[TBL] [Abstract][Full Text] [Related]
38. Ponatinib: a review of its use in adults with chronic myeloid leukaemia or Philadelphia chromosome-positive acute lymphoblastic leukaemia.
Hoy SM
Drugs; 2014 May; 74(7):793-806. PubMed ID: 24807266
[TBL] [Abstract][Full Text] [Related]
39. Ponatinib after failure of second-generation tyrosine kinase inhibitor in resistant chronic-phase chronic myeloid leukemia.
Kantarjian HM; Jabbour E; Deininger M; Abruzzese E; Apperley J; Cortes J; Chuah C; DeAngelo DJ; DiPersio J; Hochhaus A; Lipton J; Nicolini FE; Pinilla-Ibarz J; Rea D; Rosti G; Rousselot P; Shah NP; Talpaz M; Srivastava S; Ren X; Mauro M
Am J Hematol; 2022 Nov; 97(11):1419-1426. PubMed ID: 36054756
[TBL] [Abstract][Full Text] [Related]
40. Metabolite characterization of ambrisentan, in in vitro and in vivo matrices by UHPLC/QTOF/MS/MS: Detection of glutathione conjugate of epoxide metabolite evidenced by in vitro GSH trapping assay.
Johnsi Rani P; Vishnuvardhan C; Nimbalkar RD; Garg P; Satheeshkumar N
J Pharm Biomed Anal; 2018 Jun; 155():320-328. PubMed ID: 29684813
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
